BTG International Inc. products

CroFab® is the only antivenom derived exclusively from US snakes to treat all North American pit viper envenomations in adult and pediatric patients.1,2 98% of venomous snakebites in the United States are from the North American pit viper. Approved in 2000, CroFab® was designed to reduce the high incidence of hypersensitivity that occurred with previous antivenom therapy, and to provide a geographically relevant antivenom. In the years since, CroFab® has become the antivenom that healthcare professionals rely on for the treatment of North American pit viper envenomation.1,4

Voraxaze® and Leucovorin Work Synergistically. For patients receiving HDMTX therapy, intracellular leucovorin (LV) is critical to provide a source of tetrahydrofolates and restore DNA synthesis to prevent damage to normal cells.. However, LV does not help reduce circulating concentrations of MTX, which can remain dangerously high in patients with delayed MTX clearance due to impaired renal function. Voraxaze® rapidly cleaves MTX into 2 inactive metabolites to provide a nonrenal pathway for elimination.

DIGIFab neutralizes free digoxin within minutes to resolve the cardiotoxic effects and other clinical manifestations of potentially life-threatening digoxin toxicity.1,